| Ytd | 205.93% | |
| 1y | 195.00% |
| Open | 4.16 | Prev Close | 4.15 | Low | 4.03 | High | 4.24 | Mkt Cap | 294.00M |
| Vol | 171.72K | Avg Vol | 1.18M | EPS | -1.73 | P/E | -2.39 | Forward P/E | -0.89 |
| Beta | 1.92 | Short Ratio | 3.17 | Inst. Own | 98.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.31 | 200-d Avg | 3.03 | 1yr Est | 9.50 |
ZNTL News
Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DE
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clini
Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian
Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenoser
US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big ga
Mizuho analyst Graig Suvannavejh initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) wit
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clini
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinic
In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the comb
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinic
400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk
Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy
SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinic
Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June Results fro
SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clin
U.S. stocks mixed, Nasdaq up 100 points. Inflation rate surges to 3.3%. Japan's Nikkei 225 and C
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) shares are surging Friday after a Guggenheim analyst r
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clin
On track for DENALI Part 2a dose confirmation in 1H 2026 DENALI Part 2 trial topline readout expecte
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clin
Almitas Capital LLC trimmed its position in Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) by 71.4% d
On Friday, 497 companies set new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
On Monday, 721 companies achieved new lows for the year.
On Friday, 431 companies hit new 52-week lows.
On Tuesday, 242 companies hit new 52-week lows.
Upgrades
Before 10 a.m. ET Friday, 183 stocks hit new 52-week highs.
Gainers
Gainers